Xcell Therapeutics Past Earnings Performance
Past criteria checks 0/6
Xcell Therapeutics's earnings have been declining at an average annual rate of -7.6%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 43.6% per year.
Key information
-7.6%
Earnings growth rate
28.4%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 43.6% |
| Return on equity | -5,681.8% |
| Net Margin | -609.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Xcell Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,502 | -9,158 | 3,588 | 2,950 |
| 31 Dec 23 | 1,124 | -9,281 | 3,684 | 2,753 |
| 31 Dec 22 | 1,020 | -8,342 | 3,219 | 2,596 |
| 31 Dec 21 | 1,966 | -9,038 | 3,058 | 1,832 |
| 31 Dec 20 | 540 | -10,124 | 1,833 | 1,166 |
| 31 Dec 19 | 86 | -4,661 | 2,624 | 1,138 |
Quality Earnings: A373110 is currently unprofitable.
Growing Profit Margin: A373110 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A373110 is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare A373110's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A373110 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A373110 has a negative Return on Equity (-5681.77%), as it is currently unprofitable.